Use of serum amyloid protein P in preparation of related products for diagnosing and treating depression

A technology for serum amyloid and depression, applied in diagnosis, disease diagnosis, diagnostic recording/measurement, etc., can solve problems such as misdiagnosis of depression, lack of monoamine neurotransmitters, oxidative stress disorder, etc., and achieve high sensitivity and specificity Sexuality, convenient promotion and use, and easy access

Active Publication Date: 2020-01-17
BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] There are many theories about the pathogenesis and pathological changes of depression, mainly including neurogenesis disorder, monoamine neurotransmitter deficiency, oxidative stress disorder, and immune regulation disorder, but none of them have been widely accepted.
In addition, the diagnosis of depres

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of serum amyloid protein P in preparation of related products for diagnosing and treating depression
  • Use of serum amyloid protein P in preparation of related products for diagnosing and treating depression
  • Use of serum amyloid protein P in preparation of related products for diagnosing and treating depression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Embodiment 1: the collection of peripheral blood and the method for measuring the concentration of peripheral blood SAP

[0065] 1. According to the approved ethical review experimental plan and diagnostic criteria, 91 cases of healthy controls and patients with depression (without medication or drug withdrawal for more than 6 weeks) were screened out, respectively, before treatment with the antidepressant escitalopram At 1 week and 12 weeks after treatment, the severity of depression was assessed by Hamilton Depression Rating Scale (HAMD), Rapid Depressive Symptom Scale (QIDS), Young Mania Scale (YMRS) and Depression Screening Scale (PHQ9). At the same time, 5 ml of peripheral blood was drawn into an EDTA anticoagulant tube, centrifuged at 3000 rpm for 10 minutes, and the upper layer of plasma was separated, and immediately aliquoted, stored in a -80°C ultra-low temperature refrigerator, and used for later use.

[0066] 2. On the Luminex 200 (Luminex, Austin, USA) plat...

Embodiment 2

[0078] Example 2: Peripheral blood SAP is used as a biomarker for the diagnosis of depression

[0079] 1. A total of 91 age- and gender-matched depression patients and 91 healthy controls were included in this study. The basic demographic information and patient symptom assessment of each group are shown in Table 2.

[0080] Table 2: Basic demographics of subjects and evaluation of clinical symptoms of patients

[0081]

[0082]

[0083] Note: HAMD: Hamilton Depression Rating Scale; QIDS: Rapid Depressive Symptom Rating Scale; YMRS: Young Mania Scale; PHQ9: Depression Screening Scale; NA: missing value.

[0084] After plasma SAP detection, it was found that compared with the healthy control group, the plasma SAP of patients with depression increased significantly ( Picture 1-1 , p=0.002), suggesting that plasma SAP concentration may be a potential biomarker for the diagnosis of depression. Combined with the subject's body mass index (BMI) and family history indicators, t...

Embodiment 3

[0085] Example 3: Peripheral blood SAP is used as a biomarker for predicting the efficacy of antidepressants

[0086] The depressive patients enrolled in the group were given the antidepressant escitalopram for treatment, and the depressive symptom scale was evaluated at 2 weeks, 4 weeks, 8 weeks and 12 weeks after treatment ( Figure 2-1 to Figure 2-4 ). After 12 weeks of antidepressant treatment, all the scores of the patients were significantly reduced, and the symptoms improved. However, some patients did not improve their symptoms significantly. After 12 weeks, the patients were divided into a treatment effective (Responders) group and a treatment ineffective (Non-responders) group according to the treatment effect (the reduction rate of the Hamilton Depression Scale reached 50%). Among them, there were 65 patients with effective treatment and 26 patients with ineffective treatment. from Figure 2-1 to Figure 2-4 It can be seen that although antidepressants have a cert...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a use of serum amyloid protein P or a reagent for detecting the serum amyloid protein P in the preparation of a reagent or a kit for diagnosing depression, and a use in the preparation of reagent or a kit for predicting and/or judging the treatment effect of an antidepressant. The serum amyloid protein P can be used as a biomarker for diagnosing depression, has higher sensitivity and specificity for the diagnosis of depression, and meanwhile can better distinguish the curative effect of the antidepressant before administration to guide the clinical medication. Just by measuring an index of the serum amyloid protein P level in the peripheral blood, diagnosis and prediction can be performed, thereby being convenient for popularization and use.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to the application of a peripheral blood marker serum amyloid P (SAP) in the diagnosis of depression and the prediction of the curative effect of antidepressants, and the application of preparing corresponding reagents. Background technique [0002] Depression is an emotional disease characterized by persistent low mood and loss of pleasure, accompanied by appetite and sleep disorders. The global prevalence of depression is about 4.3%, and the number of patients exceeds 300 million people. It has become the leading cause of disability worldwide. According to the statistics of the World Health Organization, depression is currently the fourth largest cause of disease burden, and by 2020 depression will become the second largest cause of disease burden in the world after cardiovascular disease. [0003] There are many theories about the pathogenesis and pathological changes of depression, m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68A61B5/16
CPCG01N33/6893G01N33/9466A61B5/165G01N2800/304G01N2800/50G01N2800/52
Inventor 杨健王刚周晶晶孙作厘周佳张国富
Owner BEIJING ANDING HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap